CL2022001661A1 - Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos - Google Patents
Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismosInfo
- Publication number
- CL2022001661A1 CL2022001661A1 CL2022001661A CL2022001661A CL2022001661A1 CL 2022001661 A1 CL2022001661 A1 CL 2022001661A1 CL 2022001661 A CL2022001661 A CL 2022001661A CL 2022001661 A CL2022001661 A CL 2022001661A CL 2022001661 A1 CL2022001661 A1 CL 2022001661A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- nitrogen
- based substituents
- aspects
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950927P | 2019-12-19 | 2019-12-19 | |
| US201962950919P | 2019-12-19 | 2019-12-19 | |
| US202063198310P | 2020-10-09 | 2020-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001661A1 true CL2022001661A1 (es) | 2023-01-27 |
Family
ID=74554207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001661A CL2022001661A1 (es) | 2019-12-19 | 2022-06-17 | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos |
Country Status (20)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS58392B1 (sr) | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| BR112018005861B1 (pt) | 2015-09-23 | 2022-11-22 | Reata Pharmaceuticals, Inc | Compostos derivados de ácido oleanólico modificado com c4 para a inibição de il-17, composição farmacêutica e usos terapêuticos dos ditos compostos |
| US20240293351A1 (en) * | 2020-12-11 | 2024-09-05 | Reata Pharmaceuticals Holdings, LLC | Methods of administering synthetic triterpenoids |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE033288T2 (en) * | 2008-04-18 | 2017-11-28 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: C-17 homologated oleic acid derivatives |
| EP2279197B1 (en) * | 2008-04-18 | 2014-11-05 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the c-ring |
| RS58392B1 (sr) * | 2008-04-18 | 2019-04-30 | Reata Pharmaceuticals Inc | Antioksidantni modulatori inflamacije: derivati oleanoličke kiseline sa amino i drugim modifikacijama na c-17 |
| TWI649330B (zh) * | 2013-04-24 | 2019-02-01 | 艾伯維有限公司 | 甲基巴多索龍之2,2-二氟丙醯胺衍生物、其多晶形及其使用方法 |
| MX2021003643A (es) * | 2018-09-28 | 2021-08-19 | Sichuan Haisco Pharmaceutical Co Ltd | Derivados de terpenoides y usos de los mismos. |
-
2020
- 2020-12-18 BR BR112022011919A patent/BR112022011919A2/pt unknown
- 2020-12-18 TW TW109145170A patent/TWI889738B/zh active
- 2020-12-18 US US17/757,701 patent/US20230111914A1/en active Pending
- 2020-12-18 MX MX2022007595A patent/MX2022007595A/es unknown
- 2020-12-18 WO PCT/US2020/066073 patent/WO2021127480A1/en not_active Ceased
- 2020-12-18 KR KR1020227023129A patent/KR20220116209A/ko not_active Ceased
- 2020-12-18 PE PE2022001140A patent/PE20221662A1/es unknown
- 2020-12-18 JP JP2022537305A patent/JP2023507402A/ja active Pending
- 2020-12-18 PH PH1/2022/551493A patent/PH12022551493A1/en unknown
- 2020-12-18 AU AU2020405181A patent/AU2020405181A1/en not_active Abandoned
- 2020-12-18 IL IL293876A patent/IL293876B2/en unknown
- 2020-12-18 CR CR20220345A patent/CR20220345A/es unknown
- 2020-12-18 CA CA3159778A patent/CA3159778A1/en active Pending
- 2020-12-18 EP EP20851264.0A patent/EP4077347A1/en active Pending
- 2020-12-18 CN CN202080096545.0A patent/CN115087660A/zh active Pending
-
2022
- 2022-06-15 SA SA522432999A patent/SA522432999B1/ar unknown
- 2022-06-17 DO DO2022000127A patent/DOP2022000127A/es unknown
- 2022-06-17 CL CL2022001661A patent/CL2022001661A1/es unknown
- 2022-07-15 EC ECSENADI202255210A patent/ECSP22055210A/es unknown
- 2022-07-18 CO CONC2022/0010070A patent/CO2022010070A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020405181A1 (en) | 2022-07-14 |
| JP2023507402A (ja) | 2023-02-22 |
| KR20220116209A (ko) | 2022-08-22 |
| IL293876B2 (en) | 2026-03-01 |
| EP4077347A1 (en) | 2022-10-26 |
| CO2022010070A2 (es) | 2022-08-09 |
| US20230111914A1 (en) | 2023-04-13 |
| CN115087660A (zh) | 2022-09-20 |
| MX2022007595A (es) | 2022-07-19 |
| PE20221662A1 (es) | 2022-10-26 |
| WO2021127480A1 (en) | 2021-06-24 |
| SA522432999B1 (ar) | 2025-04-10 |
| TWI889738B (zh) | 2025-07-11 |
| TW202135828A (zh) | 2021-10-01 |
| IL293876B1 (en) | 2025-11-01 |
| ECSP22055210A (es) | 2022-08-31 |
| BR112022011919A2 (pt) | 2022-09-06 |
| PH12022551493A1 (en) | 2023-11-13 |
| DOP2022000127A (es) | 2022-09-15 |
| CA3159778A1 (en) | 2021-06-24 |
| CR20220345A (es) | 2023-01-12 |
| IL293876A (en) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022010070A2 (es) | Triterpenoides sintéticos con sustituyentes a base de nitrógeno en c-17 y métodos de uso de los mismos | |
| CL2022001671A1 (es) | Inhibidores de sos1 | |
| CO2019007863A2 (es) | Derivados de benzooxazol como inmunomoduladores | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CO2019006622A2 (es) | Derivados de pirazol como inhibidores de malt1 | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| UY37900A (es) | Nuevos derivados de rapamicina | |
| NI202000080A (es) | Inhibidores de magl | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| MX2019002750A (es) | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. | |
| CO2017002998A2 (es) | Derivados de tetrahidronaftaleno que inhiben la proteína mcl-1 | |
| MX2022001697A (es) | Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos. | |
| UY35023A (es) | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso | |
| CO2018007278A2 (es) | Derivados de ácido aminobenzoico metaazacíclico como antagonistas de la integrina pan | |
| MX2022000781A (es) | Triterpenoides sintéticos heteroaromáticos sustituidos polarmente en c17, y métodos de uso de los mismos. | |
| UY36677A (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| UY36673A (es) | Sulfonas tricíclicas como moduladores de ror y composiciones farmacéuticas que las contienen | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| MX2021003888A (es) | Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares. | |
| ECSP22007557A (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
| CL2022003206A1 (es) | Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501) | |
| CL2023002064A1 (es) | Derivados de ácido urólico sintético y métodos de uso de estos | |
| CL2020000127A1 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa. |